ArticleImmunity, inflammation and disease2026
Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan-Gastrointestinal Cancers.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan-Gastrointestinal Cancers.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveCarcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) is known as a cell adhesion receptor which could regulate proliferation and other signaling in cancer. The role of CEACAM6 in pan-gastrointestinal cancers remains largely uncharacterized. This study employed multi-omics bioinformatics to investigate the expression distribution, prognostic value, and immune function of CEACAM6 in these malignancies.
methodsUtilizing multi-omics data from The Cancer Genome Atlas (TCGA), cBioPortal, GDSC2, TIMER2.0, and TISCH databases, we assessed the CEACAM6 expression and prognostic value across pan-gastrointestinal cancers. Additionally, the potential role of CEACAM6 in the tumor immune microenvironment was explored using multi-omics data, including spatial transcriptomics data.
resultsBased on TCGA data, CEACAM6 was found to be overexpressed in pan-gastrointestinal cancers. The CEACAM6 somatic copy number alterations, DNA methylation and mutation sites were identified as potential contributors to abnormal CEACAM6 expression. The CEACAM6 expression was significantly negatively associated with the abundance of CD4 + Th1 cells across pan-gastrointestinal cancers. Furthermore, spatial transcriptomics data revealed that CEACAM6 expression was significant positively associated with malignant cells, while there was a negative correlation was observed with between CEACAM6 expression and plasma cells.
conclusionCEACAM6 exhibits high diagnostic accuracy and tumor-specific overexpression in pan-gastrointestinal cancers. CEACAM6 could promote angiogenesis/metastasis and suppress anti-tumor immunity. Spatially localized in tumors with immune cell exclusion, CEACAM6 correlates with poor survival and immune-excluded subtypes, positioning it as a therapeutic target in precision immunotherapy for pan-gastrointestinal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.